The US Food and Drug Administration revises its draft guidance on quality for eye drops and other topical ophthalmic products by adding information on microbiology-related topics on the suggestion of a California biopharma foundation and lobby group.
The agency on 28 December published revision 1 to the draft following a total of 20 comments submitted on the initial it published in October
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?